LAMA4

Summary

LAMA4 (laminin subunit alpha 4, HGNC:6484) is a protein-coding gene on chromosome 6q21, encoding Laminin subunit alpha-4 (Q16363). Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.

Laminins, a family of extracellular matrix glycoproteins, are the major noncollagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Laminins are composed of 3 non identical chains: laminin alpha, beta and gamma (formerly A, B1, and B2, respectively) and they form a cruciform structure consisting of 3 short arms, each formed by a different chain, and a long arm composed of all 3 chains. Each laminin chain is a multidomain protein encoded by a distinct gene. Several isoforms of each chain have been described. Different alpha, beta and gamma chain isomers combine to give rise to different heterotrimeric laminin isoforms which are designated by Arabic numerals in the order of their discovery, i.e. alpha1beta1gamma1 heterotrimer is laminin 1. The biological functions of the different chains and trimer molecules are largely unknown, but some of the chains have been shown to differ with respect to their tissue distribution, presumably reflecting diverse functions in vivo. This gene encodes the alpha chain isoform laminin, alpha 4. The domain structure of alpha 4 is similar to that of alpha 3, both of which resemble truncated versions of alpha 1 and alpha 2, in that approximately 1,200 residues at the N-terminus (domains IV, V and VI) have been lost. Laminin, alpha 4 contains the C-terminal G domain which distinguishes all alpha chains from the beta and gamma chains. The RNA analysis from adult and fetal tissues revealed developmental regulation of expression, however, the exact function of laminin, alpha 4 is not known. Tissue-specific utilization of alternative polyA-signal has been described in literature. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 3910 — RefSeq curated summary.

At a glance

• Gene–disease (curated): junctional epidermolysis bullosa (Definitive, GenCC) — +8 more curated relationships
• GWAS associations: 16
• Clinical variants (ClinVar): 4,541 total — 126 pathogenic, 137 likely-pathogenic
• Phenotypes (HPO): 18
• Druggable target: yes
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• MANE Select transcript: NM_001105206

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6484
Approved symbol	LAMA4
Name	laminin subunit alpha 4
Location	6q21
Locus type	gene with protein product
Status	Approved
Aliases	LAMA3
Ensembl gene	ENSG00000112769
Ensembl biotype	protein_coding
OMIM	600133
Entrez	3910

Gene structure

Transcript identifiers

Ensembl transcripts: 32 — 23 protein_coding, 5 retained_intron, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000230538, ENST00000243219, ENST00000368638, ENST00000368640, ENST00000389463, ENST00000423735, ENST00000424408, ENST00000431543, ENST00000453937, ENST00000455073, ENST00000518842, ENST00000519245, ENST00000519932, ENST00000521187, ENST00000521398, ENST00000521690, ENST00000521693, ENST00000521732, ENST00000522006, ENST00000523765, ENST00000524032, ENST00000604740, ENST00000651529, ENST00000651860, ENST00000905054, ENST00000905055, ENST00000905056, ENST00000905057, ENST00000905058, ENST00000905059, ENST00000951658, ENST00000951659

RefSeq mRNA: 5 — MANE Select: NM_001105206 NM_001105206, NM_001105207, NM_001105208, NM_001105209, NM_002290

CCDS: CCDS34514, CCDS43491, CCDS43492

Canonical transcript exons

ENST00000230538 — 39 exons

Exon	Start	End
ENSE00000762308	112114076	112114195
ENSE00000762309	112114663	112114756
ENSE00000762311	112117739	112117898
ENSE00000762312	112119156	112119311
ENSE00000762313	112120283	112120472
ENSE00000762314	112122014	112122201
ENSE00000762316	112129876	112130040
ENSE00000762317	112130968	112131101
ENSE00000762318	112132753	112132890
ENSE00000762319	112133349	112133487
ENSE00000762320	112134467	112134609
ENSE00000762322	112136123	112136254
ENSE00000762324	112139120	112139291
ENSE00000762326	112139752	112139885
ENSE00000762328	112140760	112140922
ENSE00000762329	112141358	112141503
ENSE00000762330	112142119	112142292
ENSE00000762333	112150511	112150627
ENSE00000762334	112154851	112154947
ENSE00000762335	112155565	112155706
ENSE00000762336	112158732	112158880
ENSE00000762337	112165160	112165276
ENSE00000762338	112172611	112172804
ENSE00000762340	112178121	112178232
ENSE00000762341	112185237	112185347
ENSE00000762342	112187450	112187601
ENSE00000762343	112189110	112189205
ENSE00000762344	112191636	112191850
ENSE00000839988	112115863	112115993
ENSE00000919069	112253956	112254291
ENSE00001447682	112254459	112254567
ENSE00001942586	112107931	112109582
ENSE00003529949	112128922	112129075
ENSE00003540024	112216368	112216469
ENSE00003554997	112207021	112207145
ENSE00003640406	112144794	112144933
ENSE00003644431	112201608	112201688
ENSE00003645036	112148157	112148336
ENSE00003683085	112175313	112175480

Expression profiles

Bgee: expression breadth ubiquitous, 268 present calls, max score 98.98.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.1195 / max 451.0453, expressed in 1105 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
75161	13.2815	1003
75160	11.7270	1019
75159	2.6815	808
75163	0.7963	331
75158	0.5730	278
75156	0.4927	267
75162	0.3332	206
75157	0.2341	97

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus muscularis layer	UBERON:0035833	98.98	gold quality
lower esophagus	UBERON:0013473	98.95	gold quality
nerve	UBERON:0001021	98.84	gold quality
tibial nerve	UBERON:0001323	98.84	gold quality
left uterine tube	UBERON:0001303	98.82	gold quality
peritoneum	UBERON:0002358	98.67	gold quality
omental fat pad	UBERON:0010414	98.67	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.62	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.53	gold quality
colonic epithelium	UBERON:0000397	98.47	gold quality
smooth muscle tissue	UBERON:0001135	98.46	gold quality
parietal pleura	UBERON:0002400	98.37	gold quality
body of uterus	UBERON:0009853	98.33	gold quality
sural nerve	UBERON:0015488	98.11	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.08	gold quality
adipose tissue	UBERON:0001013	97.95	gold quality
germinal epithelium of ovary	UBERON:0001304	97.86	gold quality
saphenous vein	UBERON:0007318	97.76	gold quality
pleura	UBERON:0000977	97.75	gold quality
tendon of biceps brachii	UBERON:0008188	97.65	gold quality
subcutaneous adipose tissue	UBERON:0002190	97.63	gold quality
dorsal root ganglion	UBERON:0000044	97.60	gold quality
trigeminal ganglion	UBERON:0001675	97.59	gold quality
connective tissue	UBERON:0002384	97.58	gold quality
myometrium	UBERON:0001296	97.50	gold quality
vena cava	UBERON:0004087	97.13	gold quality
urethra	UBERON:0000057	97.12	gold quality
upper lobe of left lung	UBERON:0008952	97.12	gold quality
synovial joint	UBERON:0002217	97.09	gold quality
endocervix	UBERON:0000458	97.06	gold quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	47.82
E-ANND-3	yes	18.96
E-HCAD-1	yes	17.29
E-MTAB-8410	yes	16.73
E-MTAB-6701	yes	16.26
E-CURD-112	yes	14.05
E-MTAB-5061	yes	11.60
E-GEOD-84465	yes	9.33
E-CURD-46	yes	8.63
E-HCAD-35	yes	8.48
E-MTAB-9067	yes	7.78
E-GEOD-83139	yes	7.77
E-GEOD-130148	yes	7.19
E-GEOD-93593	yes	4.55
E-MTAB-7249	yes	3.52

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXM1

miRNA regulators (miRDB)

73 targeting LAMA4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-3148	99.97	75.06	6478
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 30)

• Laminins with alpha1, alpha4, and alpha5 chains are compared to determine laminin isoform-specific promotion of adhesion and migration of human bone marrow progenitor cells. (PMID:12393739)
• Data report the identification of a splice variant of the human laminin alpha4 subunit transcript containing 21 extra nucleotides. (PMID:12445830)
• The G domain of laminin alpha4 chain is a specific, high affinity ligand for alphavbeta3 & alpha3beta1 integrin heterodimers. These integrins, with alpha6beta1, cooperatively mediate endothelial cell-alpha4 laminin interaction & blood vessel development. (PMID:12454288)
• The alpha4 laminin subunit regulates vascular endothelium cell survival. (PMID:14980521)
• laminin alpha4 LG4 module may play an important role in cell adhesion and/or vessel wall formation in the skin by interacting with syndecan-2 and/or -4. (PMID:15086543)
• Downregulation of laminin alpha4 chain expression inhibits glioma invasion (PMID:15915502)
• laminin isoform changes are associated with brain tumor invasion and angiogenesis [review] (PMID:16146715)
• This suggests that G(1121-1139) peptide-containing proteins may perform their biological functions by interacting with alphavbeta3 integrin. (PMID:16824487)
• alpha4 chain Lms have a de-adhesive function and could thus play a role in detachment, migration and invasion of renal carcinoma cells in vivo. (PMID:17533363)
• 2 novel mutations (2828C>T [Pro943Leu] & 3217C>T [Arg1073X]) in the integrin-interacting domain of the LAMA4 gene reduce its integrin binding, & cause endothelial cell loss and heart failure. (PMID:17646580)
• LAMA4 is specifically up-regulated on both mRNA and protein levels in hepatocelluar carcinoma; potential role in hepatocarcinogenesis and tumor progression. (PMID:18084776)
• Concomitant changes take place in laminin- and collagen-binding receptors. Laminin-411 reduces adhesion to laminin-511 and fibronectin, suggesting that tumor cells could utilize laminin-411 in their invasive behavior (PMID:18496706)
• LM alpha4 and beta2 have roles in in vitro migration and in vivo tumorigenicity of prostate cancer cells (PMID:19048114)
• LAMC2, LAMA4, ITGB1, ITGB3, RSPA and MMP2) are overexpressed in angiotropic melanoma cells vs. non-angiotropic melanoma cells from the same tumor (PMID:19469865)
• Data from experiment with peptide fragments suggest laminin alpha4 (and laminin alpha5) may be part of host defense response and may protect tissues from invading pathogens. (PMID:20433883)
• These results indicate that mAbs to the laminin a4 globular domain are able to inhibit tumor cell adhesion and migration on laminins 411 and 421, and that alpha6beta1 integrin and MCAM bind a4-laminins at very close sites on the globular domain (PMID:24681327)
• Laminins 411 and 421 differentially promote tumor cell migration via alpha6beta1 integrin and MCAM (CD146). (PMID:24951930)
• Oxidative stress plays a vital role in controlling expression of LAMA4 through MAPK signaling pathways, which suggests a possible pathological mechanism of pre-eclampsia. (PMID:25676580)
• LAMA4 expression is lowered in preeclamptic placentas and promotes trophoblast cell invasion, migration, and angiogenesis. hypoxia-reoxygenation decreases LAMA4 expression and decouple the relationship between LAMA4 expression and p38 and ERK activation. (PMID:26059342)
• LAMA4-integrin signalling affects chondrocyte morphology and gene expression, contributing to cluster formation in osteoarthritic chondrocytes. (PMID:26295200)
• highlight MCAM and LAMA4 as prime candidates for RCC prognosis and therapeutic targeting (PMID:26921326)
• Disruption of LAMA4, LAMA5, and LAMB2 or the laminin-receptor interaction occurs in neuromuscular diseases including Pierson syndrome and Lambert-Eaton myasthenic syndrome (LEMS). (Review) (PMID:27614294)
• High LAMA4 expression is associated with gastric cancer. (PMID:30015861)
• In diverse models, laminins alpha-4 (LAMA4) and alpha-5 (LAMA5) were differentially regulated. Immunity was associated with decreased LAMA4:LAMA5 ratio, while tolerance was associated with an increased ratio. LAMA4inhibited CD4+ T-cell proliferation and Th1, Th2, and Th17 polarization but favored Treg induction. LAMA4 and LAMA5 are coinhibitory and costimulatory ligands for human and mouse CD4 T cells, respectively. (PMID:31343575)
• High LAMA4 expression is associated with inflammation in asthma. (PMID:31553662)
• Downregulation of the LAMA4 gene inhibits the proliferation, migration, and invasion of extravillous trophoblasts to suppress the expression of vascular factors, leading to the occurrence or development of preeclampsia. (PMID:31842202)
• Laminin Subunit Alpha-4 and Osteopontin Are Glioblastoma-Selective Secreted Proteins That Are Increased in the Cerebrospinal Fluid of Glioblastoma Patients. (PMID:32628487)
• Laminin-alpha4 Is Upregulated in Both Human and Murine Models of Obesity. (PMID:34394003)
• Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer. (PMID:34414238)
• [Research Progress on the Role of Laminin Subunit Alpha 4 in Diseases]. (PMID:36861161)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lama4	ENSMUSG00000019846
rattus_norvegicus	Lama4	ENSRNOG00000000599

Paralogs (27): USH2A (ENSG00000042781), LAMC3 (ENSG00000050555), LAMA3 (ENSG00000053747), LAMC2 (ENSG00000058085), NTN1 (ENSG00000065320), NTN4 (ENSG00000074527), ATRN (ENSG00000088812), LAMB4 (ENSG00000091128), LAMB1 (ENSG00000091136), LAMA1 (ENSG00000101680), MEGF8 (ENSG00000105429), MEGF9 (ENSG00000106780), ATRNL1 (ENSG00000107518), LAMA5 (ENSG00000130702), LAMC1 (ENSG00000135862), NTN5 (ENSG00000142233), HSPG2 (ENSG00000142798), TMEFF2 (ENSG00000144339), NTN3 (ENSG00000162068), NTNG1 (ENSG00000162631), EGFLAM (ENSG00000164318), LAMB2 (ENSG00000172037), AGRN (ENSG00000188157), NTNG2 (ENSG00000196358), LAMA2 (ENSG00000196569), LAMB3 (ENSG00000196878), TMEFF1 (ENSG00000241697)

Protein

Protein identifiers

Laminin subunit alpha-4 — Q16363 (reviewed: Q16363)

Alternative names: Laminin-14 subunit alpha, Laminin-8 subunit alpha, Laminin-9 subunit alpha

All UniProt accessions (12): A0A0A0MTC7, A0A494C139, A0A494C1K8, E5RFD7, E5RFQ2, E5RHF3, E5RK79, Q16363, H0Y351, H0YAP9, H0YAQ5, Q6LET9

UniProt curated annotations — full annotation on UniProt →

Function. Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components.

Subunit / interactions. Laminin is a complex glycoprotein, consisting of three different polypeptide chains (alpha, beta, gamma), which are bound to each other by disulfide bonds into a cross-shaped molecule comprising one long and three short arms with globules at each end. Alpha-4 is a subunit of laminin-8 (laminin-411), laminin-9 (laminin-421) and laminin-14 (laminin-423).

Subcellular location. Secreted. Extracellular space. Extracellular matrix. Basement membrane.

Tissue specificity. Detected in placenta (at protein level). Detected in fibroblasts and urine (at protein level). In adult, strong expression in heart, lung, ovary small and large intestines, placenta, liver; weak or no expression in skeletal muscle, kidney, pancreas, testis, prostate, brain. High expression in fetal lung and kidney. Expression in fetal and newborn tissues is observed in certain mesenchymal cells in tissues such as smooth muscle and dermis.

Disease relevance. Cardiomyopathy, dilated, 1JJ (CMD1JJ) [MIM:615235] A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The alpha-helical domains I and II are thought to interact with other laminin chains to form a coiled coil structure. Domain G is globular.

Isoforms (3)

UniProt ID	Names	Canonical?
Q16363-1	1	yes
Q16363-2	2
Q16363-3	3

RefSeq proteins (5): NP_001098676, NP_001098677, NP_001098678, NP_001098679, NP_002281 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR001791	Laminin_G	Domain
IPR002049	LE_dom	Domain
IPR009254	Laminin_aI	Domain
IPR010307	Laminin_dom_II	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR050372	Neurexin-related_CASP	Family
IPR056863	LMN_ATRN_NET-like_EGF	Domain

Pfam: PF00053, PF02210, PF06008, PF06009, PF24973

UniProt features (74 total): glycosylation site 20, disulfide bond 19, sequence variant 10, domain 9, coiled-coil region 5, splice variant 3, sequence conflict 3, region of interest 2, signal peptide 1, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16363-F1	73.75	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (19): 82–91, 84–98, 101–110, 113–129, 132–146, 134–155, 157–166, 169–184, 187–202, 189–209, 212–221, 224–238, 273, 276, 1005–1035, 1201–1227, 1370–1402, 1617–1640, 1792–1820

Glycosylation sites (20): 39, 104, 215, 315, 465, 531, 557, 578, 581, 638, 646, 742, 758, 761, 787, 810, 1093, 1288, 1366, 1418

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-3000157	Laminin interactions
R-HSA-3000171	Non-integrin membrane-ECM interactions
R-HSA-3000178	ECM proteoglycans
R-HSA-8874081	MET activates PTK2 signaling
R-HSA-9638630	Attachment of bacteria to epithelial cells
R-HSA-9913351	Formation of the dystrophin-glycoprotein complex (DGC)
R-HSA-9925563	Developmental Lineage of Pancreatic Ductal Cells
R-HSA-1474244	Extracellular matrix organization
R-HSA-162582	Signal Transduction
R-HSA-6806834	Signaling by MET
R-HSA-8875878	MET promotes cell motility
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases

MSigDB gene sets: 687 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GSE45365_NK_CELL_VS_CD8A_DC_UP, WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, LI_CISPLATIN_RESISTANCE_DN, AP1_01, JI_RESPONSE_TO_FSH_UP, TSENG_IRS1_TARGETS_UP, XU_GH1_AUTOCRINE_TARGETS_UP, GOBP_FORMATION_OF_PRIMARY_GERM_LAYER, JAEGER_METASTASIS_DN, LI_PROSTATE_CANCER_EPIGENETIC, MODULE_493, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER, TOMLINS_PROSTATE_CANCER_DN

GO Biological Process (5): cell adhesion (GO:0007155), regulation of cell adhesion (GO:0030155), regulation of cell migration (GO:0030334), regulation of embryonic development (GO:0045995), negative regulation of cold-induced thermogenesis (GO:0120163)

GO Molecular Function (3): signaling receptor binding (GO:0005102), extracellular matrix structural constituent (GO:0005201), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), basement membrane (GO:0005604), extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Extracellular matrix organization	3
MET promotes cell motility	1
Biofilm formation	1
Non-integrin membrane-ECM interactions	1
Developmental Cell Lineages of the Exocrine Pancreas	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by MET	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
extracellular matrix	2
cellular anatomical structure	2
cellular process	1
cell adhesion	1
regulation of cellular process	1
cell migration	1
regulation of cell motility	1
embryo development	1
regulation of multicellular organismal development	1
negative regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
protein binding	1
structural molecule activity	1
binding	1
external encapsulating structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

2594 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LAMA4	LAMB3	Q13751	983
LAMA4	LAMC2	Q13753	982
LAMA4	LAMB1	P07942	920
LAMA4	COL17A1	Q9UMD9	853
LAMA4	LAMC1	P11047	818
LAMA4	ITGB1	P05556	804
LAMA4	FN1	P02751	793
LAMA4	ITGA6	P23229	783
LAMA4	ITGB4	P16144	767
LAMA4	MCAM	P43121	732
LAMA4	COL4A2	P08572	730
LAMA4	ME1	P48163	728
LAMA4	COL4A1	P02462	725
LAMA4	ITGA7	Q13683	682
LAMA4	IGBP1	P78318	656

IntAct

41 interactions, top by confidence:

A	B	Type	Score
MCAM	CNTN1	psi-mi:“MI:0914”(association)	0.750
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
HADHA	AGRN	psi-mi:“MI:0914”(association)	0.530
LGALS1	PODXL	psi-mi:“MI:0914”(association)	0.530
LGALS3	PODXL	psi-mi:“MI:0914”(association)	0.530
TP53	LAMA4	psi-mi:“MI:2364”(proximity)	0.520
DAG1	LAMA4	psi-mi:“MI:0407”(direct interaction)	0.440
LAMA4	RTN4	psi-mi:“MI:0915”(physical association)	0.370
ATF7IP	LAMA4	psi-mi:“MI:0915”(physical association)	0.370
TNIP1	COCH	psi-mi:“MI:0914”(association)	0.350
TNIP2	TMEM178B	psi-mi:“MI:0914”(association)	0.350
	CCN1	psi-mi:“MI:0914”(association)	0.350
LGALS8	SLC22A23	psi-mi:“MI:0914”(association)	0.350
CCL3	KRBA1	psi-mi:“MI:0914”(association)	0.350
NID2	AGRN	psi-mi:“MI:0914”(association)	0.350
MANEA	AGRN	psi-mi:“MI:0914”(association)	0.350
LGALS9	PODXL	psi-mi:“MI:0914”(association)	0.350
BCAM	TNPO2	psi-mi:“MI:0914”(association)	0.350
PILRA	NID2	psi-mi:“MI:0914”(association)	0.350
CDH5	ESYT2	psi-mi:“MI:2364”(proximity)	0.270
CDH5	MYO1C	psi-mi:“MI:2364”(proximity)	0.270
	LAMA4	psi-mi:“MI:0915”(physical association)	0.000
APC	LAMA4	psi-mi:“MI:0915”(physical association)	0.000
FHL1	LAMA4	psi-mi:“MI:0915”(physical association)	0.000
LAMA4	EEF1A1	psi-mi:“MI:0915”(physical association)	0.000
BRD7	LAMA4	psi-mi:“MI:0915”(physical association)	0.000
LAMA4	MED31	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (53): LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Co-localization), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS), LAMA4 (Affinity Capture-MS)

ESM2 similar proteins: A2VE53, A5PJQ2, A5PMY6, A6H6E2, A6QP79, A8WGB1, F1QC17, O35550, O35551, O70340, O75071, O94901, P21757, P21758, P30204, P47970, P47971, P47972, P97738, P97927, Q05585, Q07065, Q15276, Q15818, Q16363, Q2LK54, Q3MI99, Q4V885, Q5EAJ6, Q5KU26, Q5RFW0, Q5RI56, Q62443, Q6AZY7, Q6P132, Q6P402, Q6ZMJ2, Q70UQ0, Q8BGQ6, Q8BMK4

Diamond homologs: A0JP86, A2ASQ1, G5ECE3, O00468, O00634, O09118, O15230, O75445, O75882, O95631, P02468, P11047, P15215, P19137, P24043, P25304, P25391, P31696, P34710, P97927, Q00174, Q01635, Q13751, Q13753, Q16363, Q16787, Q18823, Q19981, Q1LVF0, Q24567, Q24568, Q27262, Q2HXW4, Q2QI47, Q5RB89, Q5VV63, Q60675, Q61001, Q61087, Q61092

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
LAMA4	“form complex”	Laminin-9	binding
LAMA4	“form complex”	Laminin-8	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 45 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cell migration	7	10.3×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

4541 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	126
Likely pathogenic	137
Uncertain significance	1857
Likely benign	1795
Benign	278

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1047960	NM_198129.4(LAMA3):c.6319-1G>T	Pathogenic
1047961	NM_198129.4(LAMA3):c.6348_6352delinsCTGGCAAGA (p.Glu2117fs)	Pathogenic
1047962	NM_198129.4(LAMA3):c.9856G>T (p.Ala3286Ser)	Pathogenic
1068548	NM_198129.4(LAMA3):c.6469G>T (p.Glu2157Ter)	Pathogenic
1069997	NM_198129.4(LAMA3):c.5622_5635del (p.Leu1874fs)	Pathogenic
1070832	NM_198129.4(LAMA3):c.8145T>A (p.Tyr2715Ter)	Pathogenic
1070853	NC_000018.9:g.(?21478692)(21479039_?)del	Pathogenic
1071930	NM_198129.4(LAMA3):c.6100A>T (p.Lys2034Ter)	Pathogenic
1071950	NM_198129.4(LAMA3):c.9887G>A (p.Trp3296Ter)	Pathogenic
1072339	NM_198129.4(LAMA3):c.5394T>A (p.Cys1798Ter)	Pathogenic
1072501	NM_198129.4(LAMA3):c.6847_6854del (p.Ala2283fs)	Pathogenic
1074803	NC_000018.9:g.(?21484507)(21485598_?)del	Pathogenic
1075696	NM_198129.4(LAMA3):c.5568dup (p.Leu1857fs)	Pathogenic
1252054	NM_198129.4(LAMA3):c.8302C>T (p.Arg2768Ter)	Pathogenic
1321416	NM_198129.4(LAMA3):c.7204C>T (p.Arg2402Ter)	Pathogenic
1323177	NM_198129.4(LAMA3):c.5000_5003del (p.Gly1667fs)	Pathogenic
1323178	NM_198129.4(LAMA3):c.8087_8090delinsTGC (p.Asn2696fs)	Pathogenic
1350464	NM_198129.4(LAMA3):c.9617T>G (p.Leu3206Ter)	Pathogenic
1361060	NM_198129.4(LAMA3):c.9893C>A (p.Ser3298Ter)	Pathogenic
1369957	NM_198129.4(LAMA3):c.8755A>T (p.Lys2919Ter)	Pathogenic
1371125	NM_198129.4(LAMA3):c.7738del (p.Thr2580fs)	Pathogenic
1379401	NM_198129.4(LAMA3):c.5137G>T (p.Glu1713Ter)	Pathogenic
1400822	NM_198129.4(LAMA3):c.9236dup (p.Arg3081fs)	Pathogenic
1404615	NM_198129.4(LAMA3):c.5728C>T (p.Gln1910Ter)	Pathogenic
1412135	NM_198129.4(LAMA3):c.5992G>T (p.Glu1998Ter)	Pathogenic
1412583	NM_198129.4(LAMA3):c.6778G>T (p.Glu2260Ter)	Pathogenic
1417958	NM_198129.4(LAMA3):c.8284del (p.Glu2762fs)	Pathogenic
1422229	NM_198129.4(LAMA3):c.8911C>T (p.Gln2971Ter)	Pathogenic
1422425	NM_198129.4(LAMA3):c.6199C>T (p.Gln2067Ter)	Pathogenic
1441309	NM_198129.4(LAMA3):c.5119C>T (p.Gln1707Ter)	Pathogenic

SpliceAI

6475 predictions. Top by Δscore:

Variant	Effect	Δscore
6:112109581:TT:T	acceptor_gain	1.0000
6:112109582:TC:T	acceptor_loss	1.0000
6:112109583:C:A	acceptor_loss	1.0000
6:112109593:C:CT	acceptor_gain	1.0000
6:112109594:A:T	acceptor_gain	1.0000
6:112114071:CTTA:C	donor_loss	1.0000
6:112114072:TTAC:T	donor_loss	1.0000
6:112114073:TACC:T	donor_loss	1.0000
6:112114074:ACC:A	donor_loss	1.0000
6:112114075:C:A	donor_loss	1.0000
6:112114193:TAA:T	acceptor_gain	1.0000
6:112114196:C:CC	acceptor_gain	1.0000
6:112114201:A:AC	acceptor_gain	1.0000
6:112114659:TCA:T	donor_loss	1.0000
6:112114660:CACCT:C	donor_loss	1.0000
6:112114661:A:C	donor_loss	1.0000
6:112114662:C:CA	donor_loss	1.0000
6:112114753:TGAC:T	acceptor_gain	1.0000
6:112114757:C:CC	acceptor_gain	1.0000
6:112114758:T:A	acceptor_loss	1.0000
6:112115895:C:CA	donor_gain	1.0000
6:112117751:ATCCT:A	donor_gain	1.0000
6:112119152:TTAC:T	donor_loss	1.0000
6:112119154:A:AG	donor_loss	1.0000
6:112119308:TCAC:T	acceptor_gain	1.0000
6:112119309:CACC:C	acceptor_gain	1.0000
6:112119310:ACCTG:A	acceptor_loss	1.0000
6:112119311:CCTG:C	acceptor_loss	1.0000
6:112119313:T:A	acceptor_loss	1.0000
6:112120281:A:AC	donor_gain	1.0000

AlphaMissense

12090 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:112109535:A:G	C1792R	0.999
6:112114676:C:A	W1731C	0.999
6:112114676:C:G	W1731C	0.999
6:112201641:C:G	C157S	0.999
6:112201642:A:T	C157S	0.999
6:112109450:C:G	C1820S	0.998
6:112109451:A:G	C1820R	0.998
6:112109451:A:T	C1820S	0.998
6:112109534:C:G	C1792S	0.998
6:112109535:A:T	C1792S	0.998
6:112114087:C:T	G1772E	0.998
6:112114195:A:T	V1736D	0.998
6:112114678:A:G	W1731R	0.998
6:112114678:A:T	W1731R	0.998
6:112115945:C:G	R1677P	0.998
6:112122053:C:G	R1479P	0.998
6:112139811:G:C	S1017R	0.998
6:112139811:G:T	S1017R	0.998
6:112139813:T:G	S1017R	0.998
6:112191749:C:G	C202S	0.998
6:112191750:A:T	C202S	0.998
6:112191803:C:G	C184S	0.998
6:112191804:A:T	C184S	0.998
6:112191848:C:G	C169S	0.998
6:112191849:A:T	C169S	0.998
6:112201613:A:C	C166W	0.998
6:112201614:C:A	C166F	0.998
6:112201614:C:G	C166S	0.998
6:112201614:C:T	C166Y	0.998
6:112201615:A:T	C166S	0.998

dbSNP variants (sampled 300 via entrez): RS1000047452 (6:112222957 A>G), RS1000064484 (6:112129778 C>T), RS1000099053 (6:112174602 C>G), RS1000108408 (6:112216935 C>A), RS1000136128 (6:112156829 A>G), RS1000176610 (6:112233815 A>G,T), RS1000183895 (6:112206738 A>G), RS1000208755 (6:112250017 G>A,T), RS1000223880 (6:112147477 T>C), RS1000242629 (6:112109882 T>C), RS1000250929 (6:112157087 C>T), RS1000309173 (6:112243204 G>C,T), RS1000361076 (6:112149964 A>G), RS1000383232 (6:112243415 A>G), RS1000456661 (6:112137047 A>T)

Disease associations

OMIM: gene MIM:600133 | disease phenotypes: MIM:615235, MIM:226650, MIM:226700, MIM:245660, MIM:619783, MIM:619784, MIM:192600, MIM:600996, MIM:604772, MIM:194200, MIM:302045, MIM:607346, MIM:616399, MIM:608583, MIM:178500, MIM:601144

GenCC curated gene-disease

Disease	Classification	Inheritance
laryngo-onycho-cutaneous syndrome	Definitive	Autosomal recessive
junctional epidermolysis bullosa	Definitive	Autosomal recessive
dilated cardiomyopathy 1JJ	Strong	Autosomal dominant
junctional epidermolysis bullosa, non-Herlitz type	Strong	Autosomal recessive
junctional epidermolysis bullosa Herlitz type	Strong	Autosomal recessive
epidermolysis bullosa, junctional 2A, intermediate	Strong	Autosomal recessive
epidermolysis bullosa, junctional 2B, severe	Strong	Autosomal recessive
generalized junctional epidermolysis bullosa non-Herlitz type	Supportive	Autosomal recessive
familial isolated dilated cardiomyopathy	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
dilated cardiomyopathy 1JJ	Limited	AD

Mondo (25): dilated cardiomyopathy 1JJ (MONDO:0014095), junctional epidermolysis bullosa, non-Herlitz type (MONDO:0009180), junctional epidermolysis bullosa (MONDO:0017612), junctional epidermolysis bullosa Herlitz type (MONDO:0009182), laryngo-onycho-cutaneous syndrome (MONDO:0009513), epidermolysis bullosa, junctional 2A, intermediate (MONDO:0030746), epidermolysis bullosa, junctional 2B, severe (MONDO:0030747), cardiomyopathy (MONDO:0004994), dilated cardiomyopathy (MONDO:0005021), arrhythmogenic right ventricular cardiomyopathy (MONDO:0016587), familial hypertrophic cardiomyopathy (MONDO:0024573), catecholaminergic polymorphic ventricular tachycardia 1 (MONDO:0011484), Wolff-Parkinson-White syndrome (MONDO:0008685), dilated cardiomyopathy 3B (MONDO:0010542), hypertrophic cardiomyopathy (MONDO:0005045)

Orphanet (21): Familial isolated dilated cardiomyopathy (Orphanet:154), Localized junctional epidermolysis bullosa (Orphanet:251393), Intermediate generalized junctional epidermolysis bullosa (Orphanet:79402), Junctional epidermolysis bullosa inversa (Orphanet:79405), OBSOLETE: Junctional epidermolysis bullosa, non-Herlitz type (Orphanet:89840), Junctional epidermolysis bullosa (Orphanet:305), Laryngo-onycho-cutaneous syndrome (Orphanet:2407), Severe generalized junctional epidermolysis bullosa (Orphanet:79404), Rare cardiomyopathy (Orphanet:167848), Dilated cardiomyopathy (Orphanet:217604), Inherited arrhythmogenic cardiomyopathy (Orphanet:247), Rare familial disorder with hypertrophic cardiomyopathy (Orphanet:99739), Catecholaminergic polymorphic ventricular tachycardia (Orphanet:3286), Rare hypertrophic cardiomyopathy (Orphanet:217569), Brugada syndrome (Orphanet:130)

HPO phenotypes

18 total (20 of 18 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000407	Sensorineural hearing impairment
HP:0000969	Edema
HP:0001635	Congestive heart failure
HP:0001644	Dilated cardiomyopathy
HP:0001727	Thromboembolic stroke
HP:0002875	Exertional dyspnea
HP:0003198	Myopathy
HP:0003457	EMG abnormality
HP:0003584	Late onset
HP:0003596	Middle age onset
HP:0011462	Young adult onset
HP:0011675	Arrhythmia
HP:0012378	Fatigue
HP:0012664	Reduced left ventricular ejection fraction
HP:0012764	Orthopnea
HP:0025169	Left ventricular systolic dysfunction
HP:0100578	Lipoatrophy
HP:0001716	Wolff-Parkinson-White syndrome
HP:0001639	Hypertrophic cardiomyopathy

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST001664_14	Amyotrophic lateral sclerosis	7.000000e-07
GCST002550_24	Allergic rhinitis	4.000000e-07
GCST004611_138	High light scatter reticulocyte count	6.000000e-09
GCST004612_87	High light scatter reticulocyte percentage of red cells	4.000000e-09
GCST008103_72	Bipolar disorder	8.000000e-07
GCST008570_7	Composite immunoglobulin trait (IgA x IgG/IgM)	4.000000e-07
GCST009391_29	Metabolite levels	3.000000e-06
GCST90020024_592	A body shape index	2.000000e-08
GCST90020024_593	A body shape index	9.000000e-12
GCST90020024_594	A body shape index	3.000000e-08
GCST90020025_1082	Waist-to-hip ratio adjusted for BMI	1.000000e-10
GCST90020025_1083	Waist-to-hip ratio adjusted for BMI	3.000000e-08
GCST90020027_1107	Waist-hip index	1.000000e-10
GCST90020027_1108	Waist-hip index	4.000000e-08
GCST90020029_1418	Waist circumference adjusted for body mass index	3.000000e-09
GCST90020029_1419	Waist circumference adjusted for body mass index	2.000000e-12

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007986	reticulocyte count
EFO:0010350	cholesteryl ester 22:6 measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (15)

Descriptor	Name	Tree numbers
D019571	Arrhythmogenic Right Ventricular Dysplasia	C14.240.400.145; C14.280.238.028; C14.280.400.145; C16.131.240.400.145
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100
D009202	Cardiomyopathies	C14.280.238
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D024741	Cardiomyopathy, Hypertrophic, Familial	C14.280.238.100.500; C14.280.484.048.750.070.160.500; C16.320.160
D016109	Epidermolysis Bullosa, Junctional	C16.131.831.493.170; C16.320.850.275.170; C17.800.804.493.170; C17.800.827.275.170; C17.800.865.410.170
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D017180	Tachycardia, Ventricular	C14.280.067.845.940; C14.280.123.875.940; C23.550.073.845.940
D014927	Wolff-Parkinson-White Syndrome	C14.280.067.780.977; C14.280.123.750.977; C16.131.240.400.980
C563409	Arrhythmogenic Right Ventricular Dysplasia, Familial, 2 (supp.)
C580047	Dmd-Associated Dilated Cardiomyopathy (supp.)
C537032	Laryngo onycho cutaneous syndrome (supp.)
C537198	Spinocerebellar ataxia 19 (supp.)
C542540	Spinocerebellar ataxia 22 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2364187 (PROTEIN COMPLEX GROUP)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

80 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, increases methylation, decreases expression, increases expression	4
trichostatin A	increases expression, affects cotreatment	3
sodium arsenite	affects methylation, decreases expression, increases abundance, increases expression	3
Estradiol	decreases expression, affects expression, affects cotreatment	3
methylmercuric chloride	decreases expression, increases expression	2
cobaltous chloride	decreases secretion, decreases expression	2
belinostat	increases expression, affects cotreatment	2
Troglitazone	increases expression	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Doxorubicin	increases expression	2
Endosulfan	decreases expression	2
Progesterone	affects cotreatment, decreases expression, increases expression	2
Tobacco Smoke Pollution	increases expression, affects expression	2
Valproic Acid	affects expression, increases expression	2
Aflatoxin B1	increases methylation, increases expression	2
bisphenol F	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
geldanamycin	increases expression	1
2,4,6-tribromophenol	increases expression	1
testosterone enanthate	affects expression	1
propionaldehyde	decreases expression	1
pirinixic acid	increases activity, increases expression, affects binding	1
methylselenic acid	increases expression	1
decabromobiphenyl ether	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
tetrabromobisphenol A	increases expression	1
N-acetyl-4-benzoquinoneimine	affects response to substance	1

Cellosaurus cell lines

2 cell lines: 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9I8	Ubigene HEK293 LAMA4 KO	Transformed cell line	Female
CVCL_RY71	HEK293 rLN8	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00587223	PHASE3	TERMINATED	Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)
NCT06917690	PHASE3	RECRUITING	A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
NCT00170183	PHASE3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	PHASE3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	PHASE3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	PHASE3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	PHASE3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	PHASE3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	PHASE3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	PHASE3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	PHASE3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	PHASE3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	PHASE3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	PHASE3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	PHASE3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	PHASE3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
NCT07116473	PHASE3	NOT_YET_RECRUITING	To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT03578029	PHASE2	TERMINATED	Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa